REPLIGEN CORP Costs and Expenses
REPLIGEN CORP (RGEN) reported Costs and Expenses of $190.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-07-29
- REPLIGEN CORP costs and expenses for the quarter ending 2026-06-30 was $190.15M, a 12.87% increase year-over-year.
- REPLIGEN CORP costs and expenses for the quarter ending 2026-03-31 was $178.31M, a 9.67% increase year-over-year.
- REPLIGEN CORP costs and expenses for the quarter ending 2025-12-31 was $180.04M, a 11.76% decline year-over-year.
- REPLIGEN CORP costs and expenses for the quarter ending 2025-09-30 was $171.98M, a 5.70% increase year-over-year.
- REPLIGEN CORP costs and expenses for fiscal 2025 was $683.09M, a 2.02% increase from fiscal 2024.
- REPLIGEN CORP costs and expenses for fiscal 2024 was $669.55M, a 14.52% increase from fiscal 2023.
- REPLIGEN CORP costs and expenses for fiscal 2023 was $584.66M, a 1.35% increase from fiscal 2022.
- REPLIGEN CORP costs and expenses for fiscal 2022 was $576.87M, a 14.62% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $190.15M 10-Q · filed 2026-07-29 | $368.47M 10-Q · filed 2026-07-29 | $548.51M derived: sum of 3 quarters · filed 2026-07-29 | $720.49M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $178.31M 10-Q · filed 2026-05-06 | $358.36M derived: sum of 2 quarters · filed 2026-05-06 | $530.34M derived: sum of 3 quarters · filed 2026-05-06 | $698.81M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $180.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $352.02M derived: sum of 2 quarters · filed 2026-02-26 | $520.50M derived: sum of 3 quarters · filed 2026-07-29 | $683.09M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $171.98M 10-Q · filed 2025-11-04 | $340.45M derived: sum of 2 quarters · filed 2026-07-29 | $503.04M 10-Q · filed 2025-11-04 | $707.09M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $168.47M 10-Q · filed 2026-07-29 | $331.06M 10-Q · filed 2026-07-29 | $535.11M derived: sum of 3 quarters · filed 2026-07-29 | $697.82M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $162.59M 10-Q · filed 2026-05-06 | $366.64M derived: sum of 2 quarters · filed 2026-05-06 | $529.35M derived: sum of 3 quarters · filed 2026-05-06 | $682.72M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $204.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $366.75M derived: sum of 2 quarters · filed 2026-02-26 | $520.12M derived: sum of 3 quarters · filed 2026-02-26 | $669.55M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $162.70M 10-Q · filed 2025-11-04 | $316.07M derived: sum of 2 quarters · filed 2025-11-04 | $465.50M 10-Q · filed 2025-11-04 | $622.25M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $153.37M 10-Q · filed 2025-08-07 | $152.59M 10-Q · filed 2024-07-30 | $302.80M 10-Q · filed 2025-08-07 | $301.90M 10-Q · filed 2024-07-30 | $459.55M derived: sum of 3 quarters · filed 2026-02-26 | $596.05M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $149.43M 10-Q · filed 2025-04-29 | $149.31M 10-Q · filed 2024-05-01 | $306.18M derived: sum of 2 quarters · filed 2026-02-26 | $442.68M derived: sum of 3 quarters · filed 2026-02-26 | $582.57M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $156.75M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | $293.25M derived: sum of 2 quarters · filed 2026-02-26 | $433.14M derived: sum of 3 quarters · filed 2026-02-26 | $584.66M 10-K · filed 2026-02-26 | $584.19M 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $136.50M 10-Q/A · filed 2024-11-18 | $136.38M 10-Q · filed 2023-10-31 | $276.39M derived: sum of 2 quarters · filed 2024-11-18 | $427.91M 10-Q/A · filed 2024-11-18 | $427.56M 10-Q · filed 2023-10-31 | $565.84M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-06-30 | $139.89M 10-Q/A · filed 2024-11-18 | $139.77M 10-Q · filed 2023-08-02 | $291.41M 10-Q/A · filed 2024-11-18 | $291.17M 10-Q · filed 2023-08-02 | $429.33M derived: sum of 3 quarters · filed 2025-03-14 | $577.41M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-03-31 | $151.52M 10-Q/A · filed 2024-11-18 | $151.40M 10-Q · filed 2023-05-02 | $289.45M derived: sum of 2 quarters · filed 2025-03-14 | $437.52M derived: sum of 3 quarters · filed 2025-03-14 | $581.99M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2022-12-31 | $137.93M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $286.00M derived: sum of 2 quarters · filed 2025-03-14 | $430.47M derived: sum of 3 quarters · filed 2025-03-14 | $576.87M 10-K · filed 2025-03-14 | ||||
| 2022-09-30 | $148.08M 10-Q/A · filed 2024-11-18 | $292.54M derived: sum of 2 quarters · filed 2024-11-18 | $438.94M 10-Q/A · filed 2024-11-18 | $588.03M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-06-30 | $144.47M 10-Q/A · filed 2024-11-18 | $290.87M 10-Q/A · filed 2024-11-18 | $439.95M derived: sum of 3 quarters · filed 2024-11-18 | $572.98M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-03-31 | $146.40M 10-Q/A · filed 2024-11-18 | $295.49M derived: sum of 2 quarters · filed 2024-11-18 | $428.51M derived: sum of 3 quarters · filed 2024-11-18 | $543.23M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2021-12-31 | $149.09M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $282.11M derived: sum of 2 quarters · filed 2024-11-18 | $396.83M derived: sum of 3 quarters · filed 2024-11-18 | $503.29M 10-K/A · filed 2024-11-18 | ||||
| 2021-09-30 | $133.02M 10-Q · filed 2022-11-01 | $247.74M derived: sum of 2 quarters · filed 2022-11-01 | $354.20M 10-Q · filed 2022-11-01 | $445.43M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $114.72M 10-Q · filed 2022-08-02 | $221.17M 10-Q · filed 2022-08-02 | $312.40M derived: sum of 3 quarters · filed 2023-02-22 | $385.50M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $106.45M 10-Q · filed 2022-04-27 | $197.68M derived: sum of 2 quarters · filed 2023-02-22 | $270.78M derived: sum of 3 quarters · filed 2023-02-22 | $338.71M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $91.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $164.33M derived: sum of 2 quarters · filed 2023-02-22 | $232.25M derived: sum of 3 quarters · filed 2023-02-22 | $296.44M 10-K · filed 2023-02-22 | ||||
| 2020-09-30 | $73.10M 10-Q · filed 2021-10-28 | $141.02M derived: sum of 2 quarters · filed 2021-10-28 | $205.21M 10-Q · filed 2021-10-28 | $268.79M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-06-30 | $67.92M 10-Q · filed 2021-07-27 | $132.11M 10-Q · filed 2021-07-27 | $195.69M derived: sum of 3 quarters · filed 2022-02-17 | $257.17M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2020-03-31 | $64.18M 10-Q · filed 2021-05-04 | $127.76M derived: sum of 2 quarters · filed 2022-02-17 | $189.25M derived: sum of 3 quarters · filed 2022-02-17 | $248.88M derived: sum of 4 quarters · filed 2022-02-17 | ||||
| 2019-12-31 | $63.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $125.06M derived: sum of 2 quarters · filed 2022-02-17 | $184.70M derived: sum of 3 quarters · filed 2022-02-17 | $234.16M 10-K · filed 2022-02-17 | ||||
| 2019-09-30 | $61.48M 10-Q · filed 2020-11-05 | $121.12M derived: sum of 2 quarters · filed 2020-11-05 | $170.58M 10-Q · filed 2020-11-05 | $214.67M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $59.64M 10-Q · filed 2020-07-30 | $109.10M 10-Q · filed 2020-07-30 | $153.19M derived: sum of 3 quarters · filed 2021-02-24 | $194.83M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $49.46M 10-Q · filed 2020-05-06 | $93.55M derived: sum of 2 quarters · filed 2021-02-24 | $135.19M derived: sum of 3 quarters · filed 2021-02-24 | $178.65M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $44.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $85.73M derived: sum of 2 quarters · filed 2021-02-24 | $129.19M derived: sum of 3 quarters · filed 2021-02-24 | $168.04M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $41.64M 10-Q · filed 2019-10-31 | $85.10M derived: sum of 2 quarters · filed 2019-10-31 | $123.95M 10-Q · filed 2019-10-31 | $162.30M derived: sum of 4 quarters · filed 2019-10-31 | ||||
| 2018-06-30 | $43.46M 10-Q · filed 2019-08-01 | $82.31M 10-Q · filed 2019-08-01 | $120.66M derived: sum of 3 quarters · filed 2019-08-01 | $157.65M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | $38.85M 10-Q · filed 2019-05-09 | $77.20M derived: sum of 2 quarters · filed 2019-05-09 | $114.19M derived: sum of 3 quarters · filed 2019-05-09 | $141.17M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $38.35M 10-K · filed 2018-02-22 | $75.33M derived: sum of 2 quarters · filed 2018-11-01 | $102.32M derived: sum of 3 quarters · filed 2018-11-01 | $127.23M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $36.99M 10-Q · filed 2018-11-01 | $63.97M derived: sum of 2 quarters · filed 2018-11-01 | $88.88M 10-Q · filed 2018-11-01 | $111.58M derived: sum of 4 quarters · filed 2018-11-01 | ||||
| 2017-06-30 | $26.98M 10-Q · filed 2018-08-02 | $51.90M 10-Q · filed 2018-08-02 | $74.59M derived: sum of 3 quarters · filed 2018-08-02 | $95.52M derived: sum of 4 quarters · filed 2018-08-02 | ||||
| 2017-03-31 | $24.91M 10-Q · filed 2018-05-08 | $47.61M derived: sum of 2 quarters · filed 2018-05-08 | $68.54M derived: sum of 3 quarters · filed 2018-05-08 | $91.85M derived: sum of 4 quarters · filed 2018-05-08 | ||||
| 2016-12-31 | $22.70M 10-K · filed 2018-02-22 | $43.63M derived: sum of 2 quarters · filed 2018-02-22 | $66.94M derived: sum of 3 quarters · filed 2018-02-22 | $88.57M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $20.93M 10-K · filed 2018-02-22 | $44.24M derived: sum of 2 quarters · filed 2018-02-22 | $65.87M 10-Q · filed 2017-11-09 | $85.89M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-06-30 | $23.31M 10-Q · filed 2017-08-03 | $44.94M 10-Q · filed 2017-08-03 | $64.96M derived: sum of 3 quarters · filed 2018-02-22 | $81.09M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-03-31 | $21.63M 10-K · filed 2018-02-22 | $41.65M derived: sum of 2 quarters · filed 2018-02-22 | $57.78M derived: sum of 3 quarters · filed 2018-02-22 | $74.63M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2015-12-31 | $20.02M 10-K · filed 2017-02-23 | $36.15M derived: sum of 2 quarters · filed 2017-02-23 | $52.99M derived: sum of 3 quarters · filed 2017-02-23 | $69.77M 10-K · filed 2018-02-22 | ||||
| 2015-09-30 | $16.13M 10-K · filed 2017-02-23 | $32.97M derived: sum of 2 quarters · filed 2017-02-23 | $49.75M 10-Q · filed 2016-11-03 | $66.08M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $16.85M 10-K · filed 2017-02-23 | $16.85M 10-Q · filed 2015-08-06 | $33.63M 10-Q · filed 2016-08-04 | $33.63M 10-Q · filed 2015-08-06 | $49.96M derived: sum of 3 quarters · filed 2017-02-23 | $63.02M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2015-03-31 | $16.78M 10-K · filed 2017-02-23 | $16.78M 10-Q · filed 2015-05-08 | $33.11M derived: sum of 2 quarters · filed 2017-02-23 | $46.17M derived: sum of 3 quarters · filed 2017-02-23 | $58.62M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | $16.33M 10-K · filed 2016-02-25 | $29.39M derived: sum of 2 quarters · filed 2016-02-25 | $41.84M derived: sum of 3 quarters · filed 2016-02-25 | $52.86M 10-K · filed 2017-02-23 | $52.86M 10-K · filed 2015-03-17 | |||
| 2014-09-30 | $13.06M 10-K · filed 2016-02-25 | $13.06M 10-Q · filed 2014-11-07 | $25.51M derived: sum of 2 quarters · filed 2016-02-25 | $36.52M 10-Q · filed 2015-11-05 | $36.53M 10-Q · filed 2014-11-07 | $46.72M derived: sum of 4 quarters · filed 2016-02-25 | ||
| 2014-06-30 | $12.45M 10-K · filed 2016-02-25 | $12.45M 10-Q · filed 2014-08-11 | $23.46M 10-Q · filed 2015-08-06 | $33.66M derived: sum of 3 quarters · filed 2016-02-25 | $44.44M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-03-31 | $11.02M 10-K · filed 2016-02-25 | $11.02M 10-Q · filed 2014-05-09 | $21.22M derived: sum of 2 quarters · filed 2016-02-25 | $32.00M derived: sum of 3 quarters · filed 2016-02-25 | $43.40M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2013-12-31 | $10.20M 10-K · filed 2015-03-17 | $20.98M derived: sum of 2 quarters · filed 2015-03-17 | $32.38M derived: sum of 3 quarters · filed 2015-03-17 | $45.30M 10-K · filed 2016-02-25 | $45.30M 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $10.78M 10-K · filed 2015-03-17 | $10.78M 10-Q · filed 2013-11-08 | $22.19M derived: sum of 2 quarters · filed 2015-03-17 | $35.10M 10-Q · filed 2014-11-07 | $47.50M derived: sum of 4 quarters · filed 2015-03-17 | |||
| 2013-06-30 | $11.41M 10-K · filed 2015-03-17 | $11.41M 10-Q · filed 2013-08-07 | $24.32M 10-Q · filed 2014-08-11 | $36.72M derived: sum of 3 quarters · filed 2015-03-17 | $49.64M derived: sum of 4 quarters · filed 2015-03-17 | |||
| 2013-03-31 | $12.91M 10-K · filed 2015-03-17 | $12.91M 10-Q · filed 2013-05-07 | $25.31M derived: sum of 2 quarters · filed 2015-03-17 | $38.23M derived: sum of 3 quarters · filed 2015-03-17 | $52.44M derived: sum of 4 quarters · filed 2015-03-17 | |||
| 2012-12-31 | $12.40M 10-K · filed 2014-03-14 | $25.32M derived: sum of 2 quarters · filed 2014-03-14 | $39.52M derived: sum of 3 quarters · filed 2014-03-14 | $51.18M 10-K · filed 2015-03-17 | ||||
| 2012-09-30 | $12.92M 10-K · filed 2014-03-14 | $12.92M 10-Q · filed 2012-11-08 | $27.12M derived: sum of 2 quarters · filed 2014-03-14 | $38.78M 10-Q · filed 2013-11-08 | $47.48M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2012-06-30 | $14.21M 10-K · filed 2014-03-14 | $14.21M 10-Q · filed 2012-08-09 | $25.86M 10-Q · filed 2013-08-07 | $34.57M derived: sum of 3 quarters · filed 2014-03-14 | $42.65M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2012-03-31 | $11.66M 10-K · filed 2014-03-14 | $11.66M 10-Q · filed 2012-05-10 | $20.36M derived: sum of 2 quarters · filed 2014-03-14 | $28.44M derived: sum of 3 quarters · filed 2014-03-14 | $36.21M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2011-12-31 | $8.70M 10-K · filed 2013-03-15 | $16.78M derived: sum of 2 quarters · filed 2013-03-15 | $24.56M 10-K · filed 2014-03-14 | $32.55M derived: sum of 4 quarters · filed 2013-03-15 | ||||
| 2011-09-30 | $8.08M 10-K · filed 2013-03-15 | $8.08M 10-Q · filed 2011-11-09 | $15.85M 10-Q · filed 2011-11-09 | $23.85M 10-Q · filed 2012-11-08 | $30.62M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2011-06-30 | $7.78M 10-K · filed 2013-03-15 | $7.78M 10-Q · filed 2011-08-05 | $15.77M 10-Q · filed 2012-08-09 | $22.54M derived: sum of 3 quarters · filed 2014-03-14 | $29.32M derived: sum of 4 quarters · filed 2014-03-14 | |||
| 2011-03-31 | $7.99M 10-K · filed 2013-03-15 | $7.99M 10-Q · filed 2012-05-10 | $14.76M derived: sum of 2 quarters · filed 2014-03-14 | $21.54M derived: sum of 3 quarters · filed 2014-03-14 | $27.67M 10-K · filed 2013-03-15 | |||
| 2010-12-31 | $6.77M derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14 | $13.55M derived: sum of 2 quarters · filed 2014-03-14 | $19.67M 10-K · filed 2014-03-14 | |||||
| 2010-09-30 | $6.78M 10-Q · filed 2011-11-09 | $12.90M 10-Q · filed 2011-11-09 | ||||||
| 2010-06-30 | $6.12M 10-Q · filed 2011-08-05 | |||||||
| 2010-03-31 | $26.74M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |